We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Technique Identifies Potential False Positive COVID-19 Results from RT-PCR Tests

By LabMedica International staff writers
Posted on 23 Nov 2021
Print article
Illustration
Illustration

Researchers have developed and tested a process to identify potential false-positive COVID-19 results.

The method, developed and tested by researchers at the University of Missouri School of Medicine (Columbia, MO, USA), could help other laboratories prevent unnecessary quarantining and repeated testing of people who are not actually infected.

COVID-19 testing is an important tool for managing the virus during the pandemic, and reverse transcriptase polymerase chain reaction (RT-PCR) testing is the most widely used method. But while this type of test is considered reliable, it is associated with a small number of false positive results, most easily recognized in asymptomatic, non-exposed patients. To help ensure the accuracy of positive tests, the researchers have developed a protocol for repeat testing of all positive results involving asymptomatic and unexposed patients, and in all cases in which a specimen with a positive result was located in a testing well next to another specimen with a high virus load.

The team of researchers implemented the quality control protocol in September 2020. Over an eight-week period, 24,717 RT-PCR tests were performed. Of those, 6,251 came from asymptomatic patients. In that group, 288 specimens initially returned a positive result. A second test revealed 20 of these to be false positives.

“False positive diagnoses have important implications for patient management,” said Lester Layfield, MD, professor of pathology and anatomical sciences and director of the Molecular Diagnostics Laboratory. “False positives may lead to inappropriate quarantine, delay of other necessary medical treatment or transfer to a COVID-19 ward.”

“Retesting of positive results from asymptomatic individuals revealed some technologist errors but also contamination from positive specimens in adjacent specimen wells,” added Layfield. “This study should alert the laboratory testing community of the possibility of false positive COVID-19 tests.”

Related Links:
University of Missouri School of Medicine 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.